Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Merck takes a back seat on CAR-T, handing assets to Intrexon

pharmaphorumDecember 24, 2018

Tag: Merck , CAR-T , Intrexon , engineered T-cells

PharmaSources Customer Service